UK markets close in 1 hour 10 minutes

OPKO Health, Inc. (0KCS.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
1.3095+0.0290 (+2.26%)
As of 03:05PM BST. Market open.
Full screen
Previous close1.2805
Open1.2850
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range1.2500 - 1.3201
52-week range0.8516 - 2.2315
Volume24,645
Avg. volume114,049
Market cap6.208M
Beta (5Y monthly)1.81
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results

    Conference call begins at 4:30 p.m. Eastern time todayMIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2024. First quarter business highlights include the following: Entered into an agreement with Labcorp to sell select assets of BioReference Health. The transaction includes the sale of BioReference Health’s laboratory testing businesses focused on clinical diagnostics and women’s health

  • GlobeNewswire

    OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024

    MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Tuesday, May 7, 2024. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on May 7th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participant

  • PR Newswire

    Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business

    Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health.